[go: up one dir, main page]

WO2020138835A1 - Composition pour prévenir ou traiter des maladies de la peau comportant un extrait d'euonymus alatus f. ciliatodentatus - Google Patents

Composition pour prévenir ou traiter des maladies de la peau comportant un extrait d'euonymus alatus f. ciliatodentatus Download PDF

Info

Publication number
WO2020138835A1
WO2020138835A1 PCT/KR2019/018041 KR2019018041W WO2020138835A1 WO 2020138835 A1 WO2020138835 A1 WO 2020138835A1 KR 2019018041 W KR2019018041 W KR 2019018041W WO 2020138835 A1 WO2020138835 A1 WO 2020138835A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
skin diseases
skin
prevention
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/018041
Other languages
English (en)
Korean (ko)
Inventor
이용준
김영한
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HONGCHEON INSTITUTE OF MEDICINAL HERB
Original Assignee
HONGCHEON INSTITUTE OF MEDICINAL HERB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HONGCHEON INSTITUTE OF MEDICINAL HERB filed Critical HONGCHEON INSTITUTE OF MEDICINAL HERB
Publication of WO2020138835A1 publication Critical patent/WO2020138835A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • the present invention relates to a composition for the prevention or treatment of skin diseases comprising the extract of the oleander, more specifically, the present invention administers the pharmaceutical composition, the pharmaceutical composition for the prevention or treatment of skin diseases comprising the extract of the oleander, or a fraction thereof
  • Treatment method of skin diseases comprising the step of, as a food composition for improving skin diseases, including the extract of sashimi leaf or fractions thereof, quasi-drug tree extract or quasi-drug composition for prevention or improvement of skin diseases, including fractions thereof
  • a cosmetic composition for the prevention or improvement of skin diseases comprising a fraction thereof.
  • Skin is increasingly damaged by intrinsic factors such as aging or external factors such as ultraviolet rays, external pollutants and stress, and the ability to protect the skin from these factors is weakened, thereby reducing cell protection and proliferation capacity.
  • the individual begins the regeneration process for the damaged skin, which is a reaction of the skin tissue to the damage and lasts from 2 days to 3 weeks after the skin is damaged.
  • Korean Patent Publication No. 2010-0080972 discloses Sanyacho extract using fermented tree sap that can be used to alleviate and improve skin diseases
  • Korean Patent Publication No. 2011-0086894 discloses shell or waste coral.
  • composition for external application for skin comprising a calcined powder of alkali and an alkaline calcium solution extracted from a small ingredient powder of waste shell or coral.
  • a formulation developed using natural products does not exhibit side effects, but has a disadvantage in that the therapeutic effect is insufficient, and thus there is an urgent need for supplementation.
  • the present inventors confirmed that as a result of earnest research efforts to develop an agent capable of effectively treating skin diseases without side effects, the sage extract extract effectively exhibits the effect of treating skin diseases without showing side effects.
  • the present invention was completed.
  • One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of skin diseases, including the extract of saplings or fractions thereof.
  • Another object of the present invention is to provide a method for treating skin diseases comprising the step of administering the pharmaceutical composition to a suspected skin disease subject.
  • Another object of the present invention is to provide a food composition for improving skin diseases, comprising a sapling extract or a fraction thereof.
  • Another object of the present invention is to provide a quasi-drug composition for the prevention or improvement of skin diseases comprising a sage extract or a fraction thereof.
  • Another object of the present invention is to provide a cosmetic composition for the prevention or improvement of skin diseases comprising a sapling extract or fractions thereof.
  • the ash leaf extract of the present invention has no side effects, it has been confirmed that it can effectively treat skin diseases such as psoriasis, so the ash leaf extract of the present invention can be widely used for prevention or treatment of various skin diseases.
  • Figure 1 is a graph showing the results of analyzing the cytotoxicity of the extract of sapling tree.
  • Figure 2 is a photograph showing the results of Western blot analysis showing the results of comparing the change in the phosphorylation level of Stat3 protein according to the treatment concentration of the oleander extract.
  • Figure 3 is a schematic diagram schematically showing the experimental process to verify the effectiveness of the extract of sapling tree using a skin disease animal model.
  • IMQ imiquimod
  • EAC oleiferous extract
  • CLO dermobait
  • Figure 5 is a photograph showing the change in appearance of the ear over the breeding time of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC) or dermobait (CLO).
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • Figure 6 is a graph showing the change in the thickness of the ear skin over the breeding time of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC) or dermobait (CLO).
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • FIG. 8 is an optical micrograph showing the results of staining skin tissue of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC) or dermobait (CLO) with hematoxylin and eosin.
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • One embodiment of the present invention for achieving the above object is to provide a pharmaceutical composition for the prevention or treatment of skin diseases comprising a sage extract or a fraction thereof.
  • Another embodiment of the present invention provides a preventive or therapeutic use of a skin disease comprising a sapling extract or a fraction thereof.
  • Euonymus alatus ciliatodentatus refers to a kind of deciduous tree growing at a height of about 1 to 3 m at the foot of a mountain or a hillside, and is also referred to as a sapling tree, a sapling tree.
  • the bark has gray, wart-like bark eyes, and the young branches are green. It is distinguished because it has no wings on the branches and has only mantis-like protrusions compared to the basic species, the arrow tree.
  • Young leaves can be eaten as herbs, planted mainly for ornamental purposes, and can also be used as equipment. It is distributed nationwide in Korea, and grows abroad in Japan, Russia, and China.
  • the ash tree may be purchased and used commercially, or may be used that is collected or cultivated in nature, but is not limited thereto.
  • extract of the present invention means a liquid substance obtained by immersing a desired substance in various solvents, and then extracting it for a period of time at a normal temperature or a warm state, or a solid component obtained by removing a solvent from the liquid component.
  • extract of sapling tree provided by the present invention is an extract obtained by extracting a flower, leaf, fruit, stem, root, bark, sap, etc.
  • extracts of all formulations that can be formed using the extracts themselves and the extracts such as a crude or purified product of the extract.
  • the method for extracting the mixture is not particularly limited, and can be extracted according to a method commonly used in the art.
  • Non-limiting examples of the extraction method may include a hot water extraction method, an ultrasonic extraction method, a filtration method, a reflux extraction method, and the like, which may be performed alone or in combination of two or more methods.
  • the type of the solvent used for the extraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent include water, alcohol or a mixed solvent thereof, and these may be used alone or in combination of one or more, and specifically water may be used.
  • alcohol having 1 to 4 carbon atoms may be specifically used.
  • fraction of the present invention means a result obtained by performing a fraction to separate a specific component or a specific component group from a mixture comprising various various constituents.
  • the fractionation method for obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
  • Non-limiting examples of the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed by passing through an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity) Or a chromatographic fractionation method for performing separation according to affinity), and combinations thereof.
  • a method of obtaining a fraction from the extract by treating a predetermined solvent to the extract obtained by extracting the ash tree of the present invention are examples thereof.
  • the type of fractional solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractional solvent include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane; Or mixed solvents thereof. These may be used alone or in combination of one or more, but are not limited thereto.
  • extract or fraction may be prepared and used in a dry powder form after extraction, but is not limited.
  • skin disease of the present invention means a disease in which abnormal symptoms such as inflammation, erythema, thickening, fibrosis, and keratin appear on the skin due to genetic factors, physiological factors, environmental factors, and the like.
  • the skin disease is not particularly limited as long as the symptoms can be prevented, improved, alleviated or treated by treatment with the extract of sapling or a fraction thereof, but as an example, excessive secretion of inflammatory cytokine
  • cytokine may be an inflammatory skin disease induced by, and as another example, atopic dermatitis, allergic dermatitis, psoriasis, seborrheic dermatitis, contact dermatitis, erythema, which is a type of inflammatory skin disease induced by excessive secretion of IL-6
  • It can be reflective lupus, purulent acne, or papule hives.
  • prevention of the present invention means all actions to suppress or delay skin diseases by administration of a composition containing the extract.
  • treatment of the present invention means any action in which symptoms of skin disease are improved or beneficially changed by administration of a composition containing the extract.
  • the pharmaceutical composition of the present invention may include the extract in an amount of 0.001 to 80, specifically 0.001 to 70, and more specifically 0.001 to 60% by weight based on the total weight of the composition, but is not limited thereto.
  • the pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient, or diluent commonly used in the manufacture of a pharmaceutical composition, and the carrier may include a non-naturally occurring carrier.
  • the carrier, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the pharmaceutical compositions are tablets, pills, powders, granules, capsules, suspensions, intravenous solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, transdermal formulations according to a conventional method, respectively. It can be formulated in the form of absorbents, gels, lotions, ointments, creams, patches, cataplasmas, pastes, sprays, skin emulsions, skin suspensions, transdermal delivery patches, drug-containing bandages or suppositories.
  • Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. These solid preparations may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition, lubricants such as magnesium stearate and talc may be used in addition to simple excipients.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • injectable esters such as ethyl oleate.
  • a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerogelatin may be used.
  • Another embodiment of the present invention provides a method for treating skin diseases, comprising administering the pharmaceutical composition to a suspected skin disease individual.
  • administration means the act of introducing a composition comprising said extract to an individual in an appropriate manner.
  • the term "individual" of the present invention refers to all animals, such as mice, mice, livestock, including humans, who may or may have a skin disease. As a specific example, it may be a mammal, including a human.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat the disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the individual type and severity, age, sex, activity of the drug, Sensitivity to the drug, time of administration, route of administration and rate of excretion, duration of treatment, factors including co-drugs and other factors well known in the medical arts.
  • the sapling extract may be administered at a dose of 0.01 to 500 mg/kg per day, specifically 10 to 100 mg/kg, and the administration may be administered once or several times a day.
  • the pharmaceutical composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be administered single or multiple. Considering all of the above factors, it is important to administer an amount that can achieve the maximum effect in a minimal amount without side effects, and can be easily determined by those skilled in the art.
  • the pharmaceutical composition may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally, or topically) according to the desired method, and the dosage is the patient's condition, weight, and degree of disease.
  • parenterally eg, applied intravenously, subcutaneously, intraperitoneally, or topically
  • the dosage is the patient's condition, weight, and degree of disease.
  • the route of administration and time it can be appropriately selected by those skilled in the art.
  • Another embodiment of the present invention provides a food composition for improving skin diseases, comprising a sage extract or a fraction thereof.
  • improvement means any action that at least reduces the parameters associated with the condition being treated by administration of a composition comprising said extract, e.g., the severity of symptoms.
  • food of the present invention is meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages , Vitamin complexes, health functional foods and health foods, and includes all foods in the ordinary sense.
  • the food composition of the present invention is derived from an edible tree that can be ingested on a daily basis, a high skin disease improvement effect can be expected, and thus can be very useful for health promotion purposes.
  • the functional food (functional) food (food for special health use) (food for special health use, FoSHU) in the same terms, in addition to nutrition, the biomedical control function is processed to appear efficiently, medical and medical effects are high Means food.
  • the term'function (sex)' means obtaining a useful effect for health use such as adjusting nutrients or physiological effects on the structure and function of the human body.
  • the food of the present invention can be prepared by a method commonly used in the art, and the above-described preparation can be made by adding raw materials and ingredients commonly added in the art.
  • the formulation of the food can be prepared without limitation as long as it is a formulation recognized as food.
  • the food composition of the present invention can be prepared in various types of formulations, and unlike general medicines, it has the advantage of not having side effects that can occur when taking medicines for a long time using natural substances as raw materials, and is excellent in portability.
  • the food of the invention can be consumed as an adjuvant to enhance the improvement effect of skin diseases.
  • the health food refers to food having an active health maintenance or enhancement effect compared to general food, and health supplement food means food for health supplement purposes.
  • health functional food, health food, and dietary supplement are used interchangeably.
  • the health functional food is a food prepared by adding the saffron tree extract or fractions thereof of the present invention to food materials such as beverages, teas, spices, gums, confectionery, or by encapsulation, powdering, suspension, etc. If it does, it means that it has a certain effect on health, but unlike general medicines, it has the advantage of not having side effects that can occur when taking medicines for a long time using food as a raw material.
  • the food composition may further include a physiologically acceptable carrier, and the type of the carrier is not particularly limited, and any carrier commonly used in the art may be used.
  • the food composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, and vision.
  • additional ingredients that are commonly used in food compositions to improve odor, taste, and vision.
  • minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr);
  • amino acids such as lysine, tryptophan, cysteine, and valine.
  • the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), fungicides (bleached and highly bleached, sodium hypochlorite, etc.), antioxidants (butyl hydroxyanisole (BHA), butyl hydride) Roxytoluene (BHT, etc.), colorants (such as tar pigment), colorants (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (such as MSG sodium glutamate), sweeteners (dulcin, cyclate, saccharin , Sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen sulphate, etc.), strengthening agents, emulsifiers, thickeners (foams), coating agents, gum herbicides, foam inhibitors, solvents, improvers, etc. Food additives.
  • the additive may
  • the food composition of the present invention can be used as a health drink composition, and in this case, it may contain various flavoring agents or natural carbohydrates, etc., as additional components, such as a conventional beverage.
  • the above-described natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame.
  • the ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 ml of the health drink composition of the present invention.
  • the health drink composition includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid, pectic acid salts, alginic acid, alginic acid salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohol or carbonic acid.
  • it may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage.
  • These ingredients may be used independently or in combination.
  • the proportion of these additives is not particularly important, but is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the health drink composition of the present invention.
  • Another embodiment of the present invention provides a quasi-drug composition for the prevention or improvement of skin diseases comprising the extract of sapling or a fraction thereof.
  • Another embodiment of the present invention provides a preventive or ameliorative use of skin diseases comprising a sapling extract or a fraction thereof.
  • the definition of the sapling tree, extract, fraction, skin disease, prevention and improvement is as described above.
  • the term "quasi-drug" of the present invention is a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak effect on the human body or does not act directly on the human body, Or non-machine and similar products, one of the agents used for sterilization, pesticide and similar purposes to prevent infection, used for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases Of the items that are not used as devices, machines, or devices, and those used for the purpose of having a pharmacological effect on the structure and function of a person or animal, excluding items that are not devices, machinery, or devices, and external preparations for skin and personal hygiene Includes supplies.
  • the extract of the stalk of the present invention When added to the quasi-drug composition for the purpose of preventing or improving skin diseases, the extract of the stalk of the present invention can be added as it is or used with other quasi-drug components, and can be suitably used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the quasi-drug composition is not particularly limited, but includes personal hygiene products, external skin preparations, disinfectant cleaners, shower foams, wipes, detergent soaps, hand washes, masks or ointments.
  • the external preparation for skin is not particularly limited thereto, and may be specifically used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel, or gel.
  • the personal hygiene products are not particularly limited, but may be soap, wipes, tissues, shampoo, toothpaste, hair care products, air freshener gels or cleaning gels.
  • Another embodiment of the present invention provides a cosmetic composition for the prevention or improvement of skin diseases comprising a sage extract or a fraction thereof.
  • the definition of the sapling tree, extract, fraction, skin disease, prevention and improvement is as described above.
  • the sapling extract may contain the extract in a proportion of 0.1% to 20% by weight based on the total weight of the composition, as in the pharmaceutical composition. Specifically, it is included in a ratio of 0.1 wt% to 5 wt%, more specifically 0.4 to 0.6 wt%, and even more specifically 0.5 wt% based on the total weight of the composition, but is not limited thereto.
  • ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to the extract, for example, water, surfactant, moisturizer, lower alcohol, chelating agent, fungicide, antioxidant, preservative, pigment And one or more additives selected from the group consisting of perfumes.
  • the cosmetic composition may be prepared in any conventional formulation, for example, solutions, emulsions, suspensions, pastes, creams, lotions, gels, powders, sprays, surfactant-containing cleansing, oils, soaps, It can be formulated as a liquid detergent, bath, foundation, makeup base, essence, lotion, foam, pack, soft water, sunscreen cream or sun oil, but is not limited thereto.
  • a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
  • liquid diluents such as water, ethanol or propylene glycol as carrier components, ethoxylated isostearyl alcohol, suspensions such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystals Sex cellulose, aluminum metahydroxide, bentonite, tracant, or the like can be used.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, trakant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.
  • animal oil vegetable oil, wax, paraffin, starch, trakant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide
  • trakant cellulose derivatives
  • polyethylene glycol silicone
  • bentonite silica
  • talc talc
  • zinc oxide a carrier component
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in the case of a spray, additionally chlorofluorohydrocarbon, propane /Propellant such as butane or dimethyl ether.
  • the formulation of the present invention is a surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide as a carrier component
  • Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • ingredients included in the cosmetic composition may be included in an amount generally used in the field of skin science.
  • the extract of the oleander tree was treated on a cell line of cultured human-derived skin keratinocytes capable of simulating skin psoriasis symptoms, and the change in cell viability was measured through the WST 1 assay.
  • fetal bovine serum FBS, Gibco
  • antibiotics Antibiotic antimycotic
  • DMEM Dulbecco's modified Eagle Medium
  • 37 °C and 5% CO 2 HaCaT cell line a human-derived skin keratinocyte
  • the culture was performed once every 2-3 days.
  • the collected cells were dispensed at a concentration of 3 ⁇ 10 4 cells/ml in a 96-well plate, pre-incubated for 24 hours while maintaining 37° C. and 5% CO 2 in a incubator, and various concentrations (100-800 ⁇ g/ ml) treated with extract of ash leaf tree and incubated for 24 hours. Then, water-soluble tetrazolium salt (WST-1) was treated to incubate 1 hour so that WST-1 is reduced by enzymatic action of viable cells. Then, it was measured at 450 nm using a microplate reader (FIG. 1). At this time, cells treated with the extract of oleander as a negative control were used, and cells treated with only DMSO were used as a positive control.
  • WST-1 water-soluble tetrazolium salt
  • Figure 1 is a graph showing the results of analyzing the cytotoxicity of the extract of sapling tree.
  • Example 2 Analysis of the effect of sage extract on IL-6 related signaling
  • IL-6 a kind of cytokine, is known to cause skin diseases through an inflammatory reaction, and it is known that one of the main causes of IL-6 production is phosphorylation of the Stat3 protein.
  • HaCaT cell lines were treated with M5 and various concentrations (100, 200 or 400 ⁇ g/ml) of oleander extract alone, or a combination thereof, incubated for 4 hours, and then protein was extracted from each of these cell lines.
  • Western blot analysis using protein, anti-pSTAT3 antibody or anti-STAT3 antibody and anti-rabbit IgG HRP linked antibody of each cell line was performed to quantitatively analyze the level of pSTAT3 and STAT3 protein expressed in each cell line ( Fig. 2). At this time, ⁇ -actin was used as an internal control.
  • Figure 2 is a photograph showing the results of Western blot analysis showing the results of comparing the change in the phosphorylation level of Stat3 protein according to the treatment concentration of the oleander extract.
  • Example 3 Verification of the effect of sage extract using a skin disease animal model
  • An animal model inducing skin disease was produced by applying imiquimod (IMQ), which can simulate skin psoriasis symptoms, to mouse skin.
  • IMQ imiquimod
  • the imiquimod used in the test was Aldara cream (5% imiquimod, 3M Health Care Ltd. UK), and the control group was Dermovate (clobetasol 17-propionate 0.5 mg/1 g, Glaxo Operation, UK). was used.
  • the Aldara cream was applied to the epilated ear area of a 7-week-old Balb/c mouse for 7 days to induce a skin condition similar to a skin disease, and the ointment containing the sapling extract was applied together from 2 days, Ear skin thickness and erythema levels were measured at 0, 2, 4, and 6 days respectively (FIG. 3 ).
  • the thickness of the ear skin was measured using a Digimatic Thickness Gage (Mitutoyo, Japan), and the erythema level was measured using Dermacatch ⁇ c (Colorix, Swiss).
  • the ointment containing the oleander extract was white petrolatum: 4521.6 mg, sorbitan sesquioleate: 23.86 mg, propylene glycol: 204.50 mg, hazelnut extract (5%): 250 mg, and the appropriate amount of ointment was 50°C. It was prepared by mixing in a bath. In addition, the ointment to be treated as a control was prepared to include white petrolatum, sorbitan sesquioleate, and propylene glycol. Finally, 62.5 mg of the Aldara cream was applied to the skin of the mouse and after 5 hours, 80 mg of ointment or dermobait containing hazel extract was applied.
  • Figure 3 is a schematic diagram schematically showing the experimental process to verify the effectiveness of the extract of sapling tree using a skin disease animal model.
  • FIG. 4 is a graph showing the weight change of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC), or dermobait (CLO).
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • mice treated with the extract of oleander alone showed no significant change in weight, whereas all mice treated with imiquimod (IMQ) had a reduced weight, especially . It was confirmed that the mice treated with imiquimod and dermobait (IMQ+CLO) showed the greatest weight change.
  • Figure 5 is a photograph showing the change in appearance of the ear over the breeding time of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC) or dermobait (CLO).
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • Figure 6 is a graph showing the change in the thickness of the ear skin over the breeding time of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC) or dermobait (CLO).
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • the ear skin thickness of the mouse (IMQ+Vehicle) treated with imiquimod alone was remarkably higher than that of the mouse (EAC) treated with the control (vehicle) and oleander extract alone.
  • the thickness of the increased ear skin was significantly reduced by the treatment of imiquimod, but mice treated with imiquimod and oleander extract were increased.
  • IMQ+EAC it was confirmed that the thickness of the ear skin increased by the treatment of imiquimod was slightly reduced. It was analyzed that the increase in the thickness of the ear skin was caused by an increase in skin keratin.
  • IMQ imiquimod
  • EAC oleander extract
  • CLO dermobait
  • Example 3 sacrificial Balb/c mice treated with imiquimod (IMQ), pear leaf extract (EAC), or dermobait (CLO) for 7 days were sacrificed, and the imiquimod, pear leaf extract or dermobait was applied. Skin tissue was removed. After the exfoliated tissue was fabricated, hematoxylin and eosin (H & E) staining was performed, and then observed with an optical microscope to compare the degree of damage to the skin tissue and quantify the thickness of the skin epidermis. Analysis ( Figures 8 and 9).
  • FIG. 8 is an optical micrograph showing the results of staining the skin tissue of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC), or dermobait (CLO) with hematoxylin and eosin;
  • FIG. I s a graph showing the results of quantitative analysis of the epidermal thickness of skin tissue of Balb/c mice treated with imiquimod (IMQ), oleander extract (EAC), or dermobait (CLO).
  • the present invention can significantly improve the improvement and treatment efficiency for skin diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne : une composition pharmaceutique qui permet de prévenir ou de traiter des maladies de la peau et qui comporte un extrait d'Euonymus alatus f. ciliatodentatus ou une fraction de celui-ci ; une méthode de traitement des maladies de la peau, comprenant une étape d'administration de la composition pharmaceutique au patient ; une composition alimentaire pour soulager les maladies de la peau, comportant un extrait d'Euonymus alatus f. ciliatodentatus ou une fraction de celui-ci ; une composition quasi-médicamenteuse pour prévenir ou soulager des maladies de la peau, comportant un extrait d'Euonymus alatus f. ciliatodentatus ou une fraction de celui-ci ; une composition cosmétique pour prévenir ou soulager des maladies de la peau, comportant un extrait d'Euonymus alatus f. ciliatodentatus ou une fraction de celui-ci. L'extrait d'Euonymus alatus f. ciliatodentatus selon la présente invention ne provoque pas d'effets indésirables et il a été confirmé que ledit extrait peut traiter efficacement des maladies cutanées telles que le psoriasis. De ce fait, l'extrait d'Euonymus alatus f. ciliatodentatus selon la présente invention peut être largement utilisé pour prévenir ou traiter diverses maladies de la peau.
PCT/KR2019/018041 2018-12-27 2019-12-18 Composition pour prévenir ou traiter des maladies de la peau comportant un extrait d'euonymus alatus f. ciliatodentatus Ceased WO2020138835A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180170130A KR102209664B1 (ko) 2018-12-27 2018-12-27 회잎나무 추출물을 포함하는 피부질환 예방 또는 치료용 조성물
KR10-2018-0170130 2018-12-27

Publications (1)

Publication Number Publication Date
WO2020138835A1 true WO2020138835A1 (fr) 2020-07-02

Family

ID=71128273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/018041 Ceased WO2020138835A1 (fr) 2018-12-27 2019-12-18 Composition pour prévenir ou traiter des maladies de la peau comportant un extrait d'euonymus alatus f. ciliatodentatus

Country Status (2)

Country Link
KR (1) KR102209664B1 (fr)
WO (1) WO2020138835A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331675B1 (ko) * 1994-12-30 2002-12-05 닛폰 쏘시아 가부시키가이샤 피부외용제
KR20050119838A (ko) * 2004-06-17 2005-12-22 안은화 화살나무 추출물이 함유된 비누 제조방법
KR20110083817A (ko) * 2010-01-15 2011-07-21 주식회사 알엔에스 피부 염증 개선용 화장료 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331675B1 (ko) * 1994-12-30 2002-12-05 닛폰 쏘시아 가부시키가이샤 피부외용제
KR20050119838A (ko) * 2004-06-17 2005-12-22 안은화 화살나무 추출물이 함유된 비누 제조방법
KR20110083817A (ko) * 2010-01-15 2011-07-21 주식회사 알엔에스 피부 염증 개선용 화장료 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Euonymus alatus for. ciliatodentatus (Franch. & Sav.) Hiyama", EUNYMUS ALATUS, pages 357 - 363 *
16 April 2018 (2018-04-16), Retrieved from the Internet <URL:https://blog.naver.com/yoous2923/221253312972> *

Also Published As

Publication number Publication date
KR102209664B1 (ko) 2021-01-28
KR20200080557A (ko) 2020-07-07

Similar Documents

Publication Publication Date Title
KR102152750B1 (ko) 장미 추출물을 포함하는 조성물
KR101800498B1 (ko) 미성숙 사과 추출물 또는 이로부터 분리된 화합물을 유효성분으로 포함하는 주름 개선용 조성물
KR102126470B1 (ko) 용안육 추출물을 포함하는 화장료 조성물
WO2021215882A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de péricarpe de camélia en tant que principe actif
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu&#39;ingrédient actif
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
WO2018026103A1 (fr) Composition pour la régénération cellulaire comprenant un extrait d&#39;axe floral de ginseng
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d&#39;artemisia umbelliformis
KR20150003193A (ko) 화장품 및 제약 조성물에 플라보노이드를 포함하는 엠벨리아 콘신나 추출물
WO2018190501A1 (fr) Composition anti-inflammatoire contenant un extrait de pédoncule de fleur de ginseng
KR20140131243A (ko) 진세노사이드 ｆ2를 포함하는 탈모방지 또는 발모촉진용 조성물
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
US20170135948A1 (en) Composition comprising extract of autumn soybean leaves
WO2020138835A1 (fr) Composition pour prévenir ou traiter des maladies de la peau comportant un extrait d&#39;euonymus alatus f. ciliatodentatus
WO2019139403A1 (fr) Composition contenant de la séricine, un extrait de torilis japonica et un extrait de viscum album pour la régénération de la peau, l&#39;apaisement de la peau ou la cicatrisation des plaies
WO2023022540A1 (fr) Composition de prévention de la perte de cheveux ou favorisant la pousse des cheveux comprenant un extrait de fleur de chardon-marie comme ingrédient actif
WO2020138833A1 (fr) Composition comprenant un extrait de corylus heterophylla pour la prévention ou le traitement d&#39;une maladie de la peau
KR102272637B1 (ko) 올벚나무를 포함하는 항염증용 조성물
KR102105672B1 (ko) 용안육 추출물을 포함하는 화장료 조성물
KR101695372B1 (ko) 까치밥나무 추출물을 함유하는 피부 주름 개선 및 예방용 조성물
KR102047461B1 (ko) 앉은 부채 추출물 또는 이의 분획물을 유효성분으로 포함하는 주름 개선용 조성물
WO2015005700A1 (fr) Composition permettant de favoriser la repousse des cheveux et la croissance des cheveux
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
KR102262362B1 (ko) 참외 줄기 또는 오이 줄기의 추출물을 포함하는 피부 상태 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19902360

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19902360

Country of ref document: EP

Kind code of ref document: A1